Evaluation of Digoxin for Relapsed Non-WNT, Non-SHH Medulloblastoma
H. Lee Moffitt Cancer Center and Research Institute
Summary
The purpose of this study is to evaluate the efficacy of digoxin in treating relapsed non-SHH, non-WNT medulloblastoma in pediatric and young adult patients.
Eligibility
- Age range
- 1–30 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Patients must be age \>12 months and \<30 years at the time of enrollment. * Patients must have relapsed non-WNT, non-SHH medulloblastoma confirmed by a CAP/CLIA certified assay (such as nanostring or methylation) performed on tissue from diagnosis or relapse. * Patients must have received at least one prior course of chemotherapy for their medulloblastoma. They must also have received irradiation. * Prior therapy: Therapy may not have been received more recently than the timeframes defined below: Craniospinal radiotherapy: At least 3 months have elapsed since prior cran…
Interventions
- DrugDigoxin
2.5-10 mcg/kg/day orally divided twice daily or once daily based on age on a continuous dosing schedule.
Locations (15)
- University of Alabama at Birmingham Children's of AlabamaBirmingham, Alabama
- Arkansas Childrens HospitalLittle Rock, Arkansas
- Connecticut Children's Medical CenterHartford, Connecticut
- Children's National Medical CenterWashington D.C., District of Columbia
- Nemours JacksonvilleJacksonville, Florida
- University of MiamiMiami, Florida